VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
EKSOEkso Bionics Holdings, Inc.
$25.50$62M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksEKSOEarnings History

EKSO logoEkso Bionics Holdings, Inc. (EKSO) Earnings History

Net Loss

13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$16M
● Net Loss
TTM EPS (Diluted)
$-4.40
Per share, diluted
YoY EPS Growth
-776.8%
Declining
Net Margin
-91.4%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-104.1%
Gross Margin53.5%
Return on Equity-107.6%
Return on Assets-50.0%
Record Annual Net Income-$12,292FY2013
Record Quarterly EPS$0.04Q3 2019
Consecutive Profitable Years0years
Q1 2026
Net Income-$7M
EPS (Diluted)$-2.04
YoY Growth-776.8%Declining
QoQ Growth-47.3%Declining

Loading earnings history...

Ekso Bionics Holdings, Inc. (EKSO) Earnings Overview

As of June 23, 2026, Ekso Bionics Holdings, Inc. (EKSO) reported trailing twelve-month net income of -$16M, reflecting -776.8% year-over-year growth. The company earned $-4.40 per diluted share over the past four quarters, with a net profit margin of -91.4%.

Looking at the long-term picture, EKSO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12,292 in fiscal 2013.

Ekso Bionics Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including IRBT (-$209M net income, -21.3% margin), CYBR (-$147M net income, -10.8% margin), ATAI (-$663M net income, -16142.0% margin), EKSO has room to improve margins relative to the peer group. Compare EKSO vs IRBT →

EKSO Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
EKSO logoEKSOCurrent
-$16M$-4.40-91.4%-107.6%-776.8%—
IRBT logoIRBT
-$209M$-5.99-21.3%-112.9%+55.3%
CYBR logoCYBR
-$147M$-2.90-10.8%-6.2%-38.2%
ATAI logoATAI
-$663M$-2.93-16142.0%-389.9%-212.9%
MYO logoMYO
-$15M$-0.36-38.1%-86.2%-131.3%
NVCR logoNVCR
-$173M$-1.52-20.8%-38.9%+21.8%
Best in group
Lowest in group

EKSO Historical Earnings Data (2013–2025)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$12M-3.2%-$13M$-4.91-91.4%-104.1%
2024-$11M+25.5%-$10M$-0.56-63.2%-58.4%
2023-$15M-0.8%-$15M$-1.10-83.1%-82.7%
2022-$15M-54.4%-$16M$-1.16-116.8%-120.5%
2021-$10M+38.3%-$14M$-0.88-86.8%-123.0%
2020-$16M-30.4%-$13M$-2.21-178.2%-144.8%
2019-$12M+55.1%-$17M$-2.44-87.2%-119.6%
2018-$27M+7.3%-$27M$-6.61-238.2%-238.5%
2017-$29M-24.1%-$32M$-12.27-396.1%-429.9%
2016-$23M-19.8%-$28M$-18.90-165.0%-194.0%
2015-$20M+42.0%-$22M$-15.52-226.2%-248.9%
2014-$34M-274623.4%-$17M$-34.96-633.9%-315.3%
2013$-12,292-$-12,292$-0.05-0.4%-0.4%

Download Data

Export EKSO earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

13+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

EKSO — Frequently Asked Questions

Quick answers to the most common questions about buying EKSO stock.

What is EKSO earnings per share (EPS)?

EKSO trailing twelve-month (TTM) diluted EPS is $-4.40, reflecting -776.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.

What is Ekso Bionics Holdings, Inc.'s net income?

Ekso Bionics Holdings, Inc. (EKSO) trailing twelve-month net income is $-16M as of 2025. Earnings declined -776.8% year-over-year.

Is EKSO profitable?

EKSO is not currently profitable on a TTM basis, reporting a net loss of $-16M. Net margin is -91.4%. Investors should monitor for a return to profitability.

What is EKSO's earnings growth rate?

EKSO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.

What are EKSO's profit margins?

Ekso Bionics Holdings, Inc. net profit margin is -91.4%, operating margin is -104.1%, and gross margin is +53.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -107.6%.

Is EKSO growing earnings?

EKSO earnings are declining — EPS fell -776.8% year-over-year. TTM net income dropped to $-16M. This contrasts with the 5-year CAGR of N/A.

What was EKSO's best earnings year?

Ekso Bionics Holdings, Inc.'s highest annual net income on record is $-12292.00, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.

What were EKSO's earnings last quarter?

EKSO's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-2.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.

EKSO Earnings Over Time (2013–2025)

Net income & EPS — annual and quarterly view